Search
ATG003
go.drugbank.com/drugs/DB05069InvestigationalATG003, a novel anti-angiogenic drug candidate and a formulation of mecamylamine, is currently in clinical development for neovascular age-related macular degeneration.
Obinepitide
go.drugbank.com/drugs/DB05045ExperimentalIn obinepitide, the properties of both of these hormones have been implanted into a single molecule. … Obinepitide is a synthetic analogue of two natural human hormones, PYY and Pancreatic Polypeptide, which normally are released during a meal.
ISF402
go.drugbank.com/drugs/DB06315ExperimentalISF402 is an investigational peptide tetramer which helps dispersal of insulin via zinc chelation, therefore allowing insulin hexamers to break free.
Eprotirome
go.drugbank.com/drugs/DB05035InvestigationalEprotirome which is a compound with promising properties for treatment of obesity and dyslipidemia.
BOS172722
go.drugbank.com/drugs/DB15498InvestigationalThe key role of Mps1 in the growth of cancer cells renders it an appealing target for cancer treatment, as its inhibition could lead to favorable effects. … [A187123] Normally, Mps1 supports the proper division of cancer cells, ensuring survival and replication.
MF101
go.drugbank.com/drugs/DB05052InvestigationalMF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal women.
Linaprazan
go.drugbank.com/drugs/DB20602InvestigationalThe usage of the INN stem '-prazan' in the name indicates that Linaprazan is a proton pump inhibitor, not dependent on acid activation. … Linaprazan has a monoisotopic molecular weight of 366.21 Da.
Carbon black
go.drugbank.com/drugs/DB11980InvestigationalProduced by the incomplete combustion of hydrocarbons, carbon black is an insoluble pigment [A263396] with demonstrated adverse effects on pulmonary function.
SLV319
go.drugbank.com/drugs/DB05077ExperimentalIt is developed for the treatment of obesity and other metabolic disorders. … SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor.
Goflikicept
go.drugbank.com/drugs/DB16396InvestigationalGoflikicept is under investigation in clinical trial NCT04380519 (Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe
Synonyms: Heterodimeric fusion protein that binds to IL-1 beta consisting of human extracellular domain of IL1 receptor and a mutant Fc fragment of human IGg1 and part of human IL1 receptor accessory protein